General Surgery Department, Hospital Privado Universitario de Córdoba, Córdoba, Argentina.
J Laparoendosc Adv Surg Tech A. 2024 Nov;34(11):993-999. doi: 10.1089/lap.2023.0535. Epub 2024 Aug 5.
This report aimed to analyze the outcomes of patients with obesity who were on a bariatric program during the SARS-Cov-2 pandemic outbreak and compare those who received surgery with the ones who were not operated on. This was a retrospective study between 2020 and 2021. Patients were divided into two groups: those who underwent surgery (O) and those who were not operated (NO). The evolution of the risk factors identified for severe COVID infection and death was studied (ASMBS criteria). For this study, a follow-up period of 12 months was initiated. In the O group, 83 patients were included and 99 were in the NO group. In the O group, patients with body mass index (BMI) > 35 Kg/m before surgery resolved the condition in 73.5% (61) cases, and this was done in the first 30 days by 38 (45.7%). Type 2 diabetes mellitus remission was documented in 18 patients (85.7%) of the O group, and the mean time elapsed for remission was 102.2 days ( < .01). Hypertension remitted in 66.7% (20) of the patients in group O in 82.4 days ( < .01). The subgroup of patients with obesity and one high-risk associated condition (30.2%, 25) resolved both in 44% (11) cases and one in 48% (12) cases. In the group of patients with obesity and two high-risk associated conditions (15.6%, 13), 47% (6) patients resolved the three conditions, 38% (5) resolved two conditions, and 15% (2) resolved one condition. Among the NO group, no comorbidity resolutions were recorded ( < .01). Admission because of COVID infection was necessary for 7.1% of NO and 1.2% of O ( = .04). Bariatric metabolic surgery would not increase the risk of COVID infection or of suffering serious complications resulting from it. Patients undergoing bariatric metabolic surgery rapidly resolved high-risk comorbidities and had less need for hospitalization because of SARS-CoV-2 infection.
本报告旨在分析在 SARS-Cov-2 大流行期间接受减重计划的肥胖患者的治疗结果，并比较接受手术和未接受手术的患者。这是一项 2020 年至 2021 年期间的回顾性研究。患者被分为两组：接受手术的组（O 组）和未手术的组（NO 组）。研究了与严重 COVID 感染和死亡相关的风险因素的变化（ASMBS 标准）。对于本研究，启动了为期 12 个月的随访期。在 O 组中，纳入了 83 例患者，NO 组中则纳入了 99 例患者。在 O 组中，术前 BMI>35kg/m2的患者中有 73.5%（61 例）得到解决，这在 30 天内由 38 例（45.7%）完成。O 组中 18 例（85.7%）患者的 2 型糖尿病得到缓解，缓解的平均时间为 102.2 天（<.01）。O 组中 66.7%（20 例）的高血压患者在 82.4 天内缓解（<.01）。肥胖合并一种高危相关疾病的患者亚组（30.2%，25 例）中有 44%（11 例）的患者两种疾病均得到缓解，48%（12 例）的患者一种疾病得到缓解。肥胖合并两种高危相关疾病的患者亚组（15.6%，13 例）中，有 47%（6 例）的患者三种疾病均得到缓解，38%（5 例）的患者两种疾病得到缓解，15%（2 例）的患者一种疾病得到缓解。NO 组中未记录到任何合并症的缓解（<.01）。NO 组因 COVID 感染住院的患者占 7.1%，O 组为 1.2%（=.04）。减重代谢手术不会增加 COVID 感染或由此导致的严重并发症的风险。接受减重代谢手术的患者迅速解决了高危合并症，因 SARS-CoV-2 感染住院的需求较少。
